Hims Jumps as RFK Jr. Seeks to Loosen Peptide Regulations
perigon
Last updated: April 16, 2026
Hims & Hers Health Inc. saw a significant stock price increase following an announcement by Health Secretary Robert F. Kennedy Jr. regarding upcoming changes to US drug regulations. These changes are expected to ease restrictions on several widely used peptide injections.
- Hims & Hers Health Inc.'s stock experienced a notable surge, reaching up to a 12% increase. This market reaction is directly attributed to statements made by Health Secretary Robert F. Kennedy Jr. He indicated that the U.S. drug regulators are planning to relax current limitations on approximately a dozen popular peptide injections. This regulatory adjustment is anticipated to improve access and potentially expand the market for such treatments, benefiting companies like Hims & Hers that offer these services. The broader implications for the healthcare sector, particularly for telemedicine providers specializing in peptide therapies, are significant as these changes could lead to increased demand and revenue opportunities.
